QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
NASDAQ:ABOS

Acumen Pharmaceuticals (ABOS) Price Target & Analyst Ratings

$5.59
+0.14 (+2.57%)
(As of 05/18/2023 ET)
Compare
Today's Range
$5.26
$5.71
50-Day Range
$3.59
$6.59
52-Week Range
$3.16
$10.97
Volume
149,575 shs
Average Volume
132,479 shs
Market Capitalization
$229.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.67

Acumen Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$15.75
181.75% Upside
High Prediction$22.00
Average Prediction$15.75
Low Prediction$13.00
TypeCurrent
5/18/22 to 5/18/23
1 Month Ago
4/18/22 to 4/18/23
3 Months Ago
2/17/22 to 2/17/23
1 Year Ago
5/18/21 to 5/18/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.75$16.67$17.67$21.25
Predicted Upside181.75% Upside184.25% Upside135.03% Upside94.02% Upside
Get Acumen Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.


ABOS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABOS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Acumen Pharmaceuticals Stock vs. The Competition

TypeAcumen PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside182.26% Upside1,404.87% Upside169.42% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/18/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$13.00+138.53%
3/28/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$15.00+273.13%
3/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$16.00 ➝ $13.00+223.38%
10/5/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$15.00 ➝ $22.00+130.37%
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ABOS Price Target - Frequently Asked Questions

What is Acumen Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Acumen Pharmaceuticals stock is Buy based on the current 4 buy ratings for ABOS. The average twelve-month price prediction for Acumen Pharmaceuticals is $15.75 with a high price target of $22.00 and a low price target of $13.00. Learn more on ABOS's analyst rating history.

Do Wall Street analysts like Acumen Pharmaceuticals more than its competitors?

Analysts like Acumen Pharmaceuticals more than other Medical companies. The consensus rating score for Acumen Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how ABOS compares to other companies.

Does Acumen Pharmaceuticals's stock price have much upside?

According to analysts, Acumen Pharmaceuticals's stock has a predicted upside of 173.44% based on their 12-month price targets.

What analysts cover Acumen Pharmaceuticals?

Acumen Pharmaceuticals has been rated by Cantor Fitzgerald, Credit Suisse Group, and HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ABOS) was last updated on 5/18/2023 by MarketBeat.com Staff

My Account -